Life sciences companies are set to compete in a Dragon’s Den session at the BIA’s BioProcessUK event this month.
Taking place on day two of BIA BioProcess UK, the Dragon’s Den special session is focused on next generation analytical technologies and will see six companies compete for an audience vote.
Chairing the session will be Julie Kerby, Managing Director of Technology and Process Innovation, Cell and Gene Therapy Catapult.
The companies taking part in the session include:
Biotech Cytomos will be showcasing its dielectric spectroscopy (CDS) platform and will explain how the fast and scalable CDS platform closely monitors a broad range of individual cell features simultaneously, to provide label-free, unbiased, consistent, accurate and reliable predictive analytics for biomanufacturing and other applications.
In particular, Cytomos’ CSO, Dr Lindsay Fraser will discuss how industry benefits from the platform, stating how the technology can save and optimise batches, addressing pressing industry needs for smarter, less labour-intensive, and more automated processes capable of driving down biomanufacturing costs as well as realising scale-out in the manufacture of personalised, regenerative medicines.
Ruizhi Wang, Chief Executive Officer of Abselion will explain how the company’s Amperia benchtop instrument can be used for protein quantifaction and binding assay. Wang will also discuss the automation and compatibility features of the instrument.
NanoFCM will introduce its NanoAnalyzer platform and will discuss how it’s able to determine the size and concentration of nanoparticles (NPs) whilst simultaneously identifying those loaded with cargo or presenting specific moieties with fluorescence detection.
Sparta Biodiscovery will introduce nanoformulations for next-generation therapeutics and will showcase its SPARTA (Single Particle Automated Raman Trapping Analysis) benchtop instrument that chemically analyses and characterises single nanoparticles in a fully automated, high-throughput, non-destructive label-free process.
Irubis will showcase how its mid-infrared spectrometer Monipa can be combined with a single-use flow cell and simplified data analytics through one-point calibration to enable real-time monitoring of critical parameters in bioprocessing, enhancing efficiency of process development while reducing contamination risks. The company will explain how Monipa could make infrared spectroscopy a highly practical and cost-effective inline monitoring solution for the biopharmaceutical industry.
Lastly, Refeyn will discuss how its versatile adeno-associated virus (AAV) platform can utilise mass photometry from R&D to manufacturing.
